TNFRSF8 and peripheral T-cell lymphoma, not otherwise specified: This article reports the results of the first real-world study of patient and treatment characteristics since FDA approval of brentuximab vedotin in combination with CHP for previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas.